BSP Pharmaceuticals

What BSP Pharmaceuticals does

BSP Pharmaceuticals S.p.A. is an Italian Contract Development and Manufacturing Organization (CDMO) headquartered in Latina Scalo, Italy, founded in 2006. The company provides end-to-end pharmaceutical development and manufacturing services for oncological and non-cytotoxic innovative drugs, spanning pre-clinical GLP development through cGMP clinical and commercial supply. Its business centres on three integrated service lines: Cytotoxic Services (sterile injectable and oral dosage forms for compounds at OEL below 0.01 µg/m³), Antibody-Drug Conjugate services (bioconjugation and fill-finish at a single site), and Non-Cytotoxic Services (sterile injectables up to OEB 6), with capability extensions into peptides, proteins, oligonucleotides, and nano medicines.

The technical foundation rests on a campus with two segregated manufacturing facilities designed for high-containment operation, including explosion-proof construction and 100% one-pass-through air handling. Supporting infrastructure includes in-house QC laboratories for chemical and microbiological testing, lipid-based formulation technology for temperature-, light-, and oxygen-sensitive products, and an internal Regulatory Affairs team managing DMF and CMC documentation for filings across the EU, US, and JP markets. The company has been recognized via ISO 14001:2015 and ISO 45001:2023 certifications and a 2026 ISPE FOYA finalist nomination.

BSP operates a professional-services, quote-based B2B revenue model, reaching customers via enterprise field sales and direct business development outreach from its Italian headquarters and a US commercial branch (BSP USA, INC.) in Princeton, NJ. Demand generation is heavily event-driven through participation in major pharmaceutical conferences such as CPHI, World ADC Summit, BIO International Convention, and Festival of Biologics. The company supplies products and services to more than 80 countries. Founder Aldo Braca serves as President and CEO, and overall headcount is reported in the 1001-5000 range.

Name

BSP Pharmaceuticals

Legal name

BSP Pharmaceuticals S.p.A.

Website

https://bsppharmaceuticals.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

BSP Pharmaceuticals is an Italian CDMO providing end-to-end development and manufacturing for oncological and non-cytotoxic drugs, including cytotoxic sterile injectables, ADCs, peptides, proteins, oligonucleotides, and nano medicines, serving global pharmaceutical and biotech innovators across 80+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Latina

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Others

Revenue model

1. Contract Development and Manufacturing Services: BSP operates as a CDMO providing end-to-end pharmaceutical services including development from pre-clinical GLP to cGMP manufacturing for clinical and commercial supply. Services span cytotoxic and high potent oncology drugs, non-cytotoxic compounds, ADCs, peptides, proteins, oligonucleotides, and nano medicines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

BSP Pharmaceuticals is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end pharmaceutical services for oncological and non-cytotoxic innovative drugs. The company operates two segregated facilities offering development from pre-clinical GLP through cGMP manufacturing for clinical and commercial supply of cytotoxic/high-potent oncology drugs (OEL < 0.01 µg/M³) and non-cytotoxic compounds (up to OEB 6), handling small and large molecules including ADCs (conjugation and fill-finish), peptides, proteins, oligonucleotides, and nano medicines.

Product overview

BSP Pharmaceuticals S.p.A. is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end pharmaceutical services for oncological and non-cytotoxic innovative drugs. The BSP campus hosts 2 segregated facilities for development from pre-clinical GLP to cGMP manufacturing of Cytotoxic and High Potent Oncology drugs (OEL < 0.01 µg/M3) and Non-Cytotoxic compounds (up to OEB 6). The core product portfolio consists of three integrated service lines: Cytotoxic Services (sterile injectable and oral dosage forms), ADCs (antibody-drug conjugate conjugation and fill-finish), and Non-Cytotoxic Services (sterile injectable). Facilities are designed to handle small and large molecules including ADCs, Peptides, Proteins, Oligonucleotides, and Nano Medicines. The company also offers internal QC laboratories for chemical and microbiological testing, and an internal Regulatory Affairs team for DMF and CMC support.

Differentiator

Problem solved

Functional benefit

Products and services

• Cytotoxic Services

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hovione: Portugal-based CDMO specializing in HPAPI, particle engineering, and sterile injectables with strong oncology exposure. Competes head-to-head with BSP for cytotoxic and high-potency development and manufacturing programs.
• Catalent: Major global CDMO with deep sterile injectable, biologics, and ADC capabilities through its Biologics segment. Highly comparable to BSP as a direct competitor for high-potency and ADC manufacturing programs targeting pharma and biotech sponsors.
• Carbogen Amcis: Swiss CDMO focused on highly potent and cytotoxic API development and manufacturing. Closely comparable niche specialist competitor to BSP's cytotoxic services line, particularly for early-to-mid stage oncology programs.
• Fareva: French-headquartered CDMO with sterile injectable and high-potency manufacturing capabilities across European facilities. Comparable European regional competitor for BSP's cytotoxic and non-cytotoxic parenteral services.
• Novasep: European CDMO with strong HPAPI manufacturing capabilities and ADC process development expertise. Direct competitor to BSP in cytotoxic and high-containment contract manufacturing for oncology programs.
• Piramal Pharma Solutions: Pure-play CDMO with strong high-potency API (HPAPI) and ADC capabilities. Directly comparable to BSP as a specialist in cytotoxic manufacturing and oncology-focused contract development services for global pharma.
• AGC Biologics: Global biologics CDMO offering microbial and mammalian protein, gene therapy, and bioconjugate services. Comparable to BSP for the biologics/CDMO overlap, particularly as BSP extends into peptides, proteins, and ADCs.

Broad incumbents

• WuXi STA (WuXi AppTec): Chinese-headquartered CDMO with substantial HPAPI and ADC capacity. Competes with BSP globally on cytotoxic and bioconjugation services, leveraging scale advantages and integrated small-molecule-to-biologics capabilities.
• Lonza: World's largest CDMO offering small-molecule, biologics, and cell-and-gene services. Competes with BSP across HPAPI, sterile fill-finish, and increasingly in ADC bioconjugation, though from a much broader portfolio base.

Others

• Evonik Health Care: Specialty chemicals/CDMO with CDMO services including HPAPI and lipid-based drug delivery formulations. Adjacent competitor to BSP, particularly in lipid-based formulation for sensitive oncology compounds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BSP Pharmaceuticals